code,description,last_updated
100000-9,Health informatics pioneer and the father of LOINC,2.74
100001-7,Health informatics pioneer and cofounder of LOINC,2.74
100002-5,Specimen care is maintained,2.72
100003-3,Team communication is maintained throughout care,2.72
100004-1,Demonstrates knowledge of the expected psychosocial responses to the procedure,2.72
100005-8,Demonstrates knowledge of nutritional management related to the procedure,2.72
100006-6,Demonstrates knowledge of medication management,2.72
100007-4,Demonstrates knowledge of pain management,2.72
10000-8,R wave duration in lead AVR,2.48
100008-2,Demonstrates knowledge of wound management,2.72
100009-0,Demonstrates knowledge of the procedure and expected results,2.72
100010-8,"No injury related to procedure equipment, medical supplies, or instrumentation",2.72
100011-6,No injury related to an electrical source,2.72
100012-4,Participates in decisions affecting the patient's plan of care,2.72
100013-2,Participates in the discharge process,2.72
100014-0,Psychosocial health is maintained at or improved from baseline,2.72
100015-7,No injury related to positioning due to care or procedure,2.72
10001-6,R wave duration in lead I,2.48
100016-5,No injury related to a laser source,2.72
100017-3,Perioperative nursing data set outcomes panel [PNDS],2.72
100018-1,Hospice care Note,2.72
100019-9,ALK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100020-7,GNA11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100021-5,GNAQ gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100022-3,IDH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100023-1,IDH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
10002-4,R wave duration in lead II,2.48
100024-9,SETBP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100025-6,SRSF2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100026-4,MET gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100027-2,SMAD4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100028-0,FBXW7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal,2.72
100029-8,Cancer related multigene analysis in Plasma cell-free DNA by Molecular genetics method,2.72
100030-6,Axis I: Temporal aspects score [Mainz Pain Staging System],2.72
100031-4,Axis II: Spatial aspects score [Mainz Pain Staging System],2.72
10003-2,R wave duration in lead III,2.48
100032-2,Axis III: Drug taking behavior score [Mainz Pain Staging System],2.72
100033-0,Axis IV: Utilization of the health care system score [Mainz Pain Staging System],2.72
100034-8,Provider of automated external defibrillator use,2.72
100035-5,Exam finding location of Chest,2.72
100036-3,Exam finding location of Lung,2.72
100037-1,Patient contact disposition EMS unit,2.72
100038-9,Patient evaluation disposition EMS unit,2.72
100039-7,Crew disposition for patient care EMS unit,2.72
10004-0,R wave duration in lead V1,2.48
100040-5,Patient transport disposition EMS unit,2.72
100041-3,Aminoglycoside [Susceptibility],2.72
100042-1,Atovaquone [Susceptibility],2.72
100043-9,Azithromycin+Ethambutol [Susceptibility],2.72
100044-7,Cefcapene [Susceptibility],2.72
100045-4,Cefozopran [Susceptibility],2.72
100046-2,Cefquinome [Susceptibility],2.72
100047-0,Cefteram [Susceptibility],2.72
100048-8,Clarithromycin+Ethambutol [Susceptibility],2.72
100049-6,Eravacycline [Susceptibility],2.72
100050-4,Erythromycin+Ethambutol [Susceptibility],2.72
100051-2,Ethambutol+rifAMPin [Susceptibility],2.72
100052-0,Flomoxef [Susceptibility],2.72
100053-8,Fluoroquinolone [Susceptibility],2.72
100054-6,Gamithromycin [Susceptibility],2.72
100055-3,Optochin [Susceptibility],2.72
100056-1,Panipenem [Susceptibility],2.72
10005-7,R wave duration in lead V2,2.48
100057-9,Prothionamide [Susceptibility],2.72
100058-7,Prulifloxacin [Susceptibility],2.72
100059-5,Rifapentine [Susceptibility],2.72
100060-3,Tildipirosin [Susceptibility],2.72
100061-1,Tosufloxacin [Susceptibility],2.72
100062-9,Standard Dermatology Outcome Measures panel,2.72
100063-7,Primary skin concern,2.72
100064-5,Itch severity Reporting Period - Reported,2.72
10006-5,R wave duration in lead V3,2.48
100065-2,Satisfied with treatment,2.72
100066-0,Specular microscopy panel,2.72
100067-8,Eye Image magnification,2.72
100068-6,Right eye Fixation point [Angle],2.72
100069-4,Left eye Fixation point [Angle],2.72
100070-2,Right cornea Cell density,2.72
100071-0,Left cornea Cell density,2.72
100072-8,Right cornea Coefficient of variation,2.72
10007-3,R wave duration in lead V4,2.48
100073-6,Left cornea Coefficient of variation,2.72
100074-4,Right cornea Hexagonality,2.72
100075-1,Left cornea Hexagonality,2.72
100076-9,Right cornea Endothelial cells counted,2.72
100077-7,Left cornea Endothelial cells counted,2.72
100078-5,Right cornea Endothelial cell area.min,2.72
100079-3,Left cornea Endothelial cell area.min,2.72
100080-1,Right cornea Endothelial cell area.max,2.72
10008-1,R wave duration in lead V5,2.48
100081-9,Left cornea Endothelial cell area.max,2.72
100082-7,Right cornea Endothelial cell area.mean,2.72
100083-5,Left cornea Endothelial cell area.mean,2.72
100084-3,Right cornea Cell area.standard deviation,2.72
100085-0,Left cornea Cell area.standard deviation,2.72
100086-8,Right cornea Type of Analysis method by Specular microscopy,2.72
100087-6,Toxocara canis 24-35kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100088-4,Taenia solium larva Ab bands panel - Serum by Immunoblot,2.72
100089-2,Taenia solium larva 6-8kD Ab [Presence] in Serum by Immunoblot,2.72
1000-9,DBG Ab [Presence] in Serum or Plasma from Blood product unit,2.56
100090-0,Taenia solium larva 45kD Ab [Presence] in Serum by Immunoblot,2.72
100091-8,Trypanosoma cruzi Ab [Units/volume] in Serum by Immunoassay,2.72
100092-6,Trypanosoma cruzi Ab bands panel - Serum by Immunoblot,2.72
100093-4,Trypanosoma cruzi 15-16kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100094-2,Trypanosoma cruzi 21-22kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100095-9,Trypanosoma cruzi 27-28kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100096-7,Trypanosoma cruzi 42kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100097-5,Trypanosoma cruzi 45-47kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100098-3,Trypanosoma cruzi 120-200kD IgG Ab [Presence] in Serum by Immunoblot,2.72
10009-9,R wave duration in lead V6,2.48
100099-1,Trypanosoma cruzi 160kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100100-7,Fasciola sp IgG Ab [Presence] in Serum by Immunoassay,2.72
100101-5,Fasciola sp 8-9kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100102-3,Fasciola sp 27-28kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100103-1,Fasciola sp 60kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100104-9,Fasciola sp 42kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100105-6,Filaria IgG and IgM panel - Serum,2.72
100106-4,Filaria IgG Ab [Presence] in Serum by Immunoassay,2.72
10010-7,R' wave amplitude in lead AVF,2.48
100107-2,Leishmania sp IgG Ab [Presence] in Serum by Immunoassay,2.72
100108-0,Leishmania sp IgG Ab [Units/volume] in Serum by Immunoassay,2.72
100109-8,Leishmania sp Ab bands panel - Serum by Immunoblot,2.72
100110-6,Leishmania sp 14kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100111-4,Leishmania sp 16kD IgG Ab [Presence] in Serum by Immunoblot,2.72
100112-2,Fasciola sp Ab bands panel - Serum by Immunoblot,2.72
100113-0,Helicobacter pylori Ab panel - Serum,2.72
100114-8,Toxoplasma gondii 30kD Ab [Presence] in Serum by Immunoblot,2.72
10011-5,R' wave amplitude in lead AVL,2.48
100115-5,Toxoplasma gondii 31kD Ab [Presence] in Serum by Immunoblot,2.72
100116-3,Toxoplasma gondii 33kD Ab [Presence] in Serum by Immunoblot,2.72
100117-1,Toxoplasma gondii 40kD Ab [Presence] in Serum by Immunoblot,2.72
100118-9,Toxoplasma gondii 41kD Ab [Presence] in Serum by Immunoblot,2.72
100119-7,Toxoplasma gondii 45kD Ab [Presence] in Serum by Immunoblot,2.72
100120-5,Chlamydia trachomatis Ab panel - Serum,2.72
100121-3,Chlamydia trachomatis IgA Ab [Presence] in Serum by Immunoassay,2.72
100122-1,Chlamydophila pneumoniae Ab panel - Serum,2.72
10012-3,R' wave amplitude in lead AVR,2.48
100123-9,Chlamydophila pneumoniae IgA Ab [Presence] in Serum by Immunoassay,2.72
100124-7,Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum by Immunoassay,2.72
100125-4,Chlamydophila psittaci Ab panel - Serum,2.72
100126-2,Bordetella pertussis Ab.IgG panel - Serum,2.72
100127-0,Campylobacter sp Ab panel - Serum,2.72
100128-8,Cryptococcus sp Ag panel - Serum,2.72
100129-6,Schistosoma sp Ab [Titer] in Serum by Hemagglutination,2.75
100130-4,Schistosoma mansoni Ab [Presence] in Serum by Immunoblot,2.72
10013-1,R' wave amplitude in lead I,2.48
100131-2,Schistosoma sp 8kD Ab [Presence] in Serum by Immunoblot,2.72
100132-0,Schistosoma sp 9kD Ab [Presence] in Serum by Immunoblot,2.72
100133-8,Schistosoma sp 10kD Ab [Presence] in Serum by Immunoblot,2.72
100134-6,Schistosoma sp 11kD Ab [Presence] in Serum by Immunoblot,2.72
100135-3,Schistosoma sp 12-13kD Ab [Presence] in Serum by Immunoblot,2.72
100136-1,Schistosoma sp 14-15kD Ab [Presence] in Serum by Immunoblot,2.72
100137-9,Schistosoma sp 15-16kD Ab [Presence] in Serum by Immunoblot,2.72
100138-7,Schistosoma sp 18-19kD Ab [Presence] in Serum by Immunoblot,2.72
100139-5,Schistosoma sp 22-24kD Ab [Presence] in Serum by Immunoblot,2.72
100140-3,Schistosoma sp 30-34kD Ab [Presence] in Serum by Immunoblot,2.72
100141-1,Schistosoma sp 65kD Ab [Presence] in Serum by Immunoblot,2.72
100142-9,Schistosoma sp 70kD Ab [Presence] in Serum by Immunoblot,2.72
100143-7,Schistosoma sp 80kD Ab [Presence] in Serum by Immunoblot,2.72
100144-5,Schistosoma sp 95kD Ab [Presence] in Serum by Immunoblot,2.72
100145-2,Schistosoma sp 110kD Ab [Presence] in Serum by Immunoblot,2.72
100146-0,Schistosoma sp 120kD Ab [Presence] in Serum by Immunoblot,2.72
100147-8,Toxoplasma gondii Ab bands panel - Serum by Immunoblot,2.72
100148-6,Schistosoma sp Ab bands panel - Serum by Immunoblot,2.72
10014-9,R' wave amplitude in lead II,2.48
100149-4,6-oxo-piperidine-2-carboxylate and 6(R+S)-oxo-propylpiperidine-2-carboxylate panel - Urine and Serum or Plasma,2.72
100150-2,6(R+S)-oxo-propylpiperidine-2-carboxylate [Moles/volume] in Plasma,2.72
100151-0,6-oxo-piperidine-2-carboxylate [Moles/volume] in Plasma,2.72
100152-8,6-oxo-piperidine-2-carboxylate/Creatinine [Molar ratio] in Urine,2.72
100153-6,6(R+S)-oxo-propylpiperidine-2-carboxylate/Creatinine [Molar ratio] in Urine,2.72
100154-4,Specimen collection supervision level,2.72
100155-1,Left cornea Type of Analysis method by Specular microscopy,2.72
10015-6,R' wave amplitude in lead III,2.48
100156-9,SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection,2.72
100157-7,SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing,2.72
100158-5,Microalbumin [Mass/volume] in Urine collected for unspecified duration,2.73
100159-3,Knee Society Score pre-op panel [Knee Society Score],2.73
100160-1,Knee replacement,2.73
100161-9,Charnley Functional Classification,2.73
100162-7,Knee alignment W standing X-ray measured,2.73
100163-5,Knee medial AndOr lateral instability W full extension,2.73
10016-4,R' wave amplitude in lead V1,2.48
100164-3,Knee AP instability W 90 degree flexion,2.73
100165-0,Knee range of motion,2.73
100166-8,Flexion contracture range of Knee,2.73
100167-6,Extensor lag range of Knee,2.73
100168-4,Knee pain severity with level walking,2.73
100169-2,Knee pain severity with stairs or inclines,2.73
1001-7,DBG Ab [Presence] in Serum or Plasma from Donor,2.56
100170-0,Knee feels normal,2.73
100171-8,Satisfaction with level of knee pain while sitting,2.73
10017-2,R' wave amplitude in lead V2,2.48
100172-6,Satisfaction with level of knee pain while lying in bed,2.73
100173-4,Satisfaction with knee function while getting out of bed,2.73
100174-2,Satisfaction with knee function while performing light household duties,2.73
100175-9,Satisfaction with knee function while performing recreational activities,2.73
100176-7,Expect surgery to relieve pain,2.73
100177-5,Expect surgery will improve ability to perform activities of daily living,2.73
100178-3,"Expect surgery will improve ability to perform leisure, recreational, or sports activities",2.73
100179-1,Walk without assistive mobility devices,2.73
10018-0,R' wave amplitude in lead V3,2.48
100180-9,Assistive mobility devices used,2.73
100181-7,Assistive mobility devices used due to health condition,2.73
100182-5,Duration of standing before sitting due to knee discomfort,2.73
100183-3,Duration of walking before stopping due to knee discomfort,2.73
100184-1,How bothersome is knee when walking on an uneven surface,2.73
100185-8,How bothersome is knee when turning or pivoting leg,2.73
100186-6,How bothersome is knee when climbing up or down a flight of stairs,2.73
100187-4,How bothersome is knee when getting up from a low seat without armrests,2.73
100188-2,How bothersome is knee when getting into or out of a car,2.73
100189-0,How bothersome is knee when moving laterally,2.73
100190-8,How bothersome is knee when climbing a ladder or step stool,2.73
100191-6,How bothersome is knee when carrying a bag for one block,2.73
100192-4,How bothersome is knee when squatting,2.73
100193-2,How bothersome is knee when kneeling,2.73
100194-0,How bothersome is knee when running,2.73
100195-7,Pain severity--during activity,2.73
100196-5,Pre-op total score [Knee Society Score],2.73
100197-3,Exercise activity and pain severity panel,2.73
10019-8,R' wave amplitude in lead V4,2.48
100198-1,Pre-op objective knee indicators score [Knee Society Score],2.73
100199-9,Pre-op symptoms score [Knee Society Score],2.73
100200-5,Pre-op patient expectations score [Knee Society Score],2.73
100201-3,Pre-op functional activities score [Knee Society Score],2.73
100202-1,Pre-op discretionary knee activities score [Knee Society Score],2.73
100203-9,Knee Society Score post-op panel [Knee Society Score],2.73
100204-7,Accuracy of pre-surgery expectations of pain relief,2.73
100205-4,Accuracy of pre-surgery expectations to perform activities of daily living,2.73
10020-6,R' wave amplitude in lead V5,2.48
100206-2,"Accuracy of pre-surgery expectations to perform leisure, recreational, or sports activities",2.73
100207-0,Post-op total score [Knee Society Score],2.73
100208-8,Post-op objective knee indicators score [Knee Society Score],2.73
100209-6,Post-op symptoms score [Knee Society Score],2.73
100210-4,Post-op patient expectations score [Knee Society Score],2.73
100211-2,Post-op functional activities score [Knee Society Score],2.73
100212-0,Post-op discretionary knee activities score [Knee Society Score],2.73
100213-8,Prostate cancer multigene analysis in Blood or Tissue by Molecular genetics method,2.73
10021-4,R' wave amplitude in lead V6,2.48
100214-6,Dental model prior authorization Document,2.73
100215-3,Episode of care medical records Document Transplant surgery,2.73
100216-1,Surgical synoptic report,2.81
100217-9,Synoptic report Document Surgical oncology,2.81
100218-7,Surgical oncology of colon cancer synoptic report,2.81
100219-5,Surgical oncology of melanoma cancer synoptic report,2.81
100220-3,Surgical oncology of breast cancer synoptic report,2.81
100221-1,Surgical oncology of thyroid cancer synoptic report,2.81
10022-2,R' wave duration in lead AVF,2.48
100222-9,Surgical oncology of pancreas cancer synoptic report,2.81
100223-7,Physical findings of Retina Narrative,2.73
100224-5,Cardiac left ventricular segmental wall motion by echo panel,2.73
100225-2,Bone density quantitative ultrasound study,2.73
100226-0,Small bowel capsule endoscopy study Document,2.73
100227-8,Colon capsule endoscopy study Document,2.73
100228-6,Upper gastrointestinal capsule endoscopy study Document,2.73
100229-4,Endoscopic ultrasound study Document,2.73
10023-0,R' wave duration in lead AVL,2.48
100230-2,Routine prenatal assessment panel,2.73
100231-0,Endobronchial ultrasound study,2.73
100232-8,Impacts of Events Scale-Revised panel,2.73
100233-6,Reminders brought back feelings about adverse event,2.73
100234-4,Trouble staying asleep,2.73
100235-1,Other things triggered persistent thoughts about adverse event,2.73
100236-9,Felt irritable AndOr angry,2.73
100237-7,Avoided getting upset when unintentionally thought about adverse event,2.73
100238-5,Thought about adverse event unintentionally,2.73
100239-3,Felt as if adverse event did not happen,2.73
100240-1,Avoided reminders of adverse event,2.73
100241-9,Experienced mental images of adverse event,2.73
100242-7,Easily startled,2.73
100243-5,Tried to not think of adverse event,2.73
100244-3,"Aware of feelings about adverse event, but did not address them",2.73
100245-0,Feelings about adverse event were numb,2.73
100246-8,Acted or felt the same as during adverse event,2.73
100247-6,Trouble falling asleep,2.73
10024-8,R' wave duration in lead AVR,2.48
100248-4,Waves of strong feelings about adverse event,2.73
100249-2,Tried to remove adverse event from memory,2.73
1002-5,DBG Ab [Presence] in Serum or Plasma,2.56
100250-0,Trouble concentrating,2.73
100251-8,Reminders of adverse event caused physical reactions,2.73
100252-6,Had dreams about adverse event,2.73
100253-4,Felt watchful and on-guard,2.73
100254-2,Tried not to talk about adverse event,2.73
10025-5,R' wave duration in lead I,2.48
100255-9,Total score [Impact of Event Scale-Revised],2.73
100256-7,Fallen in last 6 months,2.73
100257-5,Feel unsteady when standing or walking,2.73
100258-3,History of fall related injury,2.73
100259-1,Aware of tactile sensations,2.73
100260-9,Easy to describe thoughts AndOr feelings,2.73
100261-7,Critical of own thoughts AndOr feelings,2.73
100262-5,Able to notice distressing thoughts AndOr feelings without having to react,2.73
10026-3,R' wave duration in lead II,2.48
100263-3,Easily distracted,2.73
100264-1,Able to notice thoughts AndOr feelings without being overwhelmed,2.73
100265-8,Aware of dietary intake impact on self,2.73
100266-6,Difficult to describe thoughts AndOr feelings,2.73
100267-4,Aware of auditory stimuli,2.73
100268-2,Able to avoid immediate reaction in difficult situations,2.73
100269-0,Do things without paying attention,2.73
100270-8,Recover quickly from distressing thoughts AndOr images,2.73
10027-1,R' wave duration in lead III,2.48
100271-6,Aware of olfactory stimuli,2.73
100272-4,Aware of visual stimuli,2.73
100273-2,Aware of emotions affect on thoughts AndOr behavior,2.73
100274-0,Observing score [FFMQ],2.73
100275-7,Describing score [FFMQ],2.73
100276-5,Acting with awareness score [FFMQ],2.73
100277-3,Nonjudging score [FFMQ],2.73
100278-1,Nonreactivity score [FFMQ],2.73
100279-9,Total score [FFMQ],2.73
100280-7,Five Facet Mindfulness Questionnaire panel [FFMQ],2.73
100281-5,D Ab [Units/volume] in Serum or Plasma,2.73
100282-3,Vaccine exemption certificate,2.73
100283-1,Harris Hip Score panel [Harris Hip Score],2.73
100284-9,Walking - functional ability,2.73
100285-6,Comfortable seated position,2.73
100286-4,Able to board public transportation,2.73
100287-2,Put on shoes and socks,2.73
100288-0,Absence of deformity score [Harris Hip Score],2.73
10028-9,R' wave duration in lead V1,2.48
100289-8,Absence of hip deformity measurements,2.73
100290-6,Range of motion score [Harris Hip Score],2.73
100291-4,Total score [Harris Hip Score],2.73
100292-2,Pre-op patient satisfaction score [Knee Society Score],2.73
100293-0,Hip Flexion range of motion,2.73
100294-8,Hip Abduction range of motion,2.73
100295-5,Hip Adduction range of motion,2.73
100296-3,Hip External rotation range of motion,2.73
10029-7,R' wave duration in lead V2,2.48
100297-1,Hip Internal rotation range of motion,2.73
100298-9,Repetition count,2.73
100299-7,Post-op patient satisfaction score [Knee Society Score],2.73
100300-3,End time Unspecified body region,2.73
100301-1,Start time Unspecified body region,2.73
100302-9,Time period start and end panel Unspecified body region,2.73
100303-7,Condition certainty of presence,2.73
100304-5,Flights climbed [#] Reporting Period,2.73
10030-5,R' wave duration in lead V3,2.48
100305-2,IDH1 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method,2.73
100306-0,IDH2 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method,2.73
100307-8,Behavioral screening elder mistreatment,2.73
100308-6,Need help getting to essential places,2.73
100309-4,Activity support person,2.73
100310-2,Reliability of support person,2.73
100311-0,"Need help to make sure there is enough food, medicines or any other things needed in house",2.73
100312-8,"Person or persons that makes sure there is enough food, medicines or any other things needed in house",2.73
10031-3,R' wave duration in lead V4,2.48
100313-6,"Need help with household things such as cook meals, help feed, or provide correct medicines each day",2.73
100314-4,Need help with house cleaning or yard work,2.73
100315-1,"Need help getting out of bed, showered, or dressed",2.73
100316-9,Need help to make sure bills get paid,2.73
100317-7,Relationship of usual support person for daily activities,2.73
100318-5,Have help with finances AndOr financial decisions,2.73
100319-3,Relationship of financial support person,2.73
100320-1,Financial support person usually asks for permission before making decisions,2.73
10032-1,R' wave duration in lead V5,2.48
100321-9,Financial support person usually makes good decisions about finances,2.73
100322-7,Have access to paperwork for financial decisions made,2.73
100323-5,Financial support person forged signature,2.73
100324-3,Coercion of financial support person for signing a document in order to get money or possessions,2.73
100325-0,Experienced theft by support person,2.73
100326-8,Money spent or property sold without permission,2.73
100327-6,Stranger forged signature for financial gain,2.73
100328-4,Stranger forced document signature for financial gain,2.73
100329-2,Feared for safety due to verbal attack,2.73
1003-3,Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma,2.73
100330-0,Felt humiliated due to ridicule,2.73
100331-8,Coerced to do something,2.73
100332-6,Ignored by close friend or relative for extended period,2.73
100333-4,Physically hit or threatened,2.73
100334-2,Been physically hurt with some degree of injury,2.73
100335-9,Coerced sexual activity,2.73
100336-7,Coerced touching of private body parts of self or others,2.73
100337-5,Coerced to undress or expose private body area,2.73
100338-3,Photographed in any degree of nudity without consent,2.73
10033-9,R' wave duration in lead V6,2.48
100339-1,Experienced attempted physical restraint,2.73
100340-9,Range of motion panel Hip,2.73
100341-7,Rubella virus IgG Ab index [Units/volume] in Serum and CSF,2.73
100342-5,Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry,2.73
100343-3,Influenza virus B RNA [Presence] in Saliva (oral fluid) by NAA with probe detection,2.73
100344-1,Influenza virus A RNA [Presence] in Saliva (oral fluid) by NAA with probe detection,2.73
100345-8,Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection,2.73
100346-6,Clotting time.extrinsic coagulation system activated.platelets inhibited of Blood by Rotational TEG,2.73
10034-7,S wave amplitude in lead AVF,2.48
100347-4,Clot formation.extrinsic coagulation system activated.platelets inhibited [Time] in Blood by Rotational TEG,2.73
100348-2,Model for end-stage liver disease sodium score,2.73
100349-0,US.doppler Penis vessels W vasodilator IV,2.73
100350-8,Sesamum indicum 1 IgE Ab [Units/volume] in Serum,2.73
100351-6,Pioglitazone [Presence] in Serum or Plasma,2.73
100352-4,Rosiglitazone [Presence] in Serum or Plasma,2.73
100353-2,Norwalk Community Health Center Screening Tool [NCHC],2.73
10035-4,S wave amplitude in lead AVL,2.48
100354-0,Frequency of participating in multi-modal communication without assistance,2.73
100355-7,Frequency of participating in spoken language expression communication without assistance,2.73
100356-5,Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA [Identifier] in Specimen by NAA with probe detection,2.73
100357-3,Naloxone [Presence] in Cord tissue by Screen method,2.73
100358-1,Phentermine [Presence] in Cord tissue by Screen method,2.73
100359-9,Gliadin 33 mer peptide [Mass/volume] in Stool by Immunoassay,2.73
100360-7,Brief Resilience Scale panel [BRS],2.73
100361-5,Quickly recover from bad events,2.73
10036-2,S wave amplitude in lead AVR,2.48
100362-3,Difficulty making it through stressful events,2.73
100363-1,Easily recover from a stressful event,2.73
100364-9,Difficulty recovering from bad events,2.73
100365-6,Easily recover from difficulties,2.73
100366-4,Lengthy recovery from setbacks,2.73
100367-2,Total Score BRS,2.73
100368-0,Amino Acids Urea Cycle Panel - Serum or Plasma by LC/MS/MS,2.73
100369-8,NM Thyroid gland Views W Tl-201 IV,2.73
10037-0,S wave amplitude in lead I,2.48
100370-6,Orthopoxvirus DNA [Identifier] in Specimen by NAA with probe detection,2.73
100371-4,Titin Ab [Units/volume] in Serum by Immunoassay,2.73
100372-2,Abiraterone [Mass/volume] in Serum or Plasma,2.73
100373-0,Eucheuma IgG Ab [Units/volume] in Serum,2.73
100374-8,Aloe vera IgG Ab [Units/volume] in Serum,2.73
100375-5,Anise IgG Ab [Units/volume] in Serum,2.73
100376-3,Bamboo sprouts IgG Ab [Units/volume] in Serum,2.81
100377-1,Goat cheese IgG Ab [Units/volume] in Serum,2.73
100378-9,Sheep cheese IgG Ab [Units/volume] in Serum,2.73
100379-7,Leeks IgG Ab [Units/volume] in Serum,2.73
100380-5,Red cabbage IgG Ab [Units/volume] in Serum,2.81
100381-3,Peppermint IgG Ab [Units/volume] in Serum,2.81
100382-1,FDA package insert REMS addressed risk,2.73
100383-9,Monkeypox virus DNA [Presence] in Specimen by NAA with probe detection,2.73
100384-7,Turnip IgG Ab [Units/volume] in Serum,2.81
100385-4,Corn salad IgG Ab [Units/volume] in Serum,2.73
100386-2,Rosemary IgG Ab [Units/volume] in Serum,2.73
100387-0,Poppy Seed IgG Ab [Units/volume] in Serum,2.73
10038-8,S wave amplitude in lead II,2.48
100388-8,Cocoa IgG Ab [Units/volume] in Serum,2.73
100389-6,Pistachio IgG Ab [Units/volume] in Serum,2.73
100390-4,Sunflower Seed IgG Ab [Units/volume] in Serum,2.73
100391-2,Dates IgG Ab [Units/volume] in Serum,2.73
100392-0,Duck meat IgG Ab [Units/volume] in Serum,2.73
100393-8,"Allergen Mushroom mix 2 (Xerocomus, Boletus) IgG Ab [Units/volume] in Serum",2.73
100394-6,Astacoidea IgG Ab [Units/volume] in Serum,2.73
100395-3,Carob IgG Ab [Units/volume] in Serum,2.73
10039-6,S wave amplitude in lead III,2.48
100396-1,Rapeseed IgG Ab [Units/volume] in Serum,2.81
100397-9,Goat Meat IgG Ab [Units/volume] in Serum,2.73
100398-7,Goose meat IgG Ab [Units/volume] in Serum,2.73
100399-5,Ostrich meat IgG Ab [Units/volume] in Serum,2.73
100400-1,Quail meat IgG Ab [Units/volume] in Serum,2.73
100401-9,Rabbit meat IgG Ab [Units/volume] in Serum,2.73
100402-7,Venison meat IgG Ab [Units/volume] in Serum,2.73
100403-5,Guineafowl IgG Ab [Units/volume] in Serum,2.73
10040-4,S wave amplitude in lead V1,2.48
100404-3,Horse meat IgG Ab [Units/volume] in Serum,2.73
100405-0,Kefir IgG Ab [Units/volume] in Serum,2.73
100406-8,Butter IgG Ab [Units/volume] in Serum,2.73
100407-6,Camembert cheese IgG Ab [Units/volume] in Serum,2.73
100408-4,Emmental cheese IgG Ab [Units/volume] in Serum,2.73
100409-2,Processed cheese IgG Ab [Units/volume] in Serum,2.73
1004-1,Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells,2.73
100410-0,Curd cheese IgG Ab [Units/volume] in Serum,2.73
100411-8,Sugar Beet IgG Ab [Units/volume] in Serum,2.73
10041-2,S wave amplitude in lead V2,2.48
100412-6,Chinese cabbage IgG Ab [Units/volume] in Serum,2.81
100413-4,Fennel Fresh IgG Ab [Units/volume] in Serum,2.73
100414-2,Gourd IgG Ab [Units/volume] in Serum,2.73
100415-9,Kale IgG Ab [Units/volume] in Serum,2.73
100416-7,Savoy cabbage IgG Ab [Units/volume] in Serum,2.73
100417-5,Vitis sp leaf IgG Ab [Units/volume] in Serum,2.73
100418-3,Liquorice IgG Ab [Units/volume] in Serum,2.73
100419-1,Snow pea IgG Ab [Units/volume] in Serum,2.73
10042-0,S wave amplitude in lead V3,2.48
100420-9,Fava bean IgG Ab [Units/volume] in Serum,2.73
100421-7,Chickpea IgG Ab [Units/volume] in Serum,2.81
100422-5,Common Chicory IgG Ab [Units/volume] in Serum,2.81
100423-3,Allergy Mushroom Mix 1 (Button + oyster + Shiitaki + chanterelle mushroom) IgG Ab [Units/volume] in Serum,2.73
100424-1,8(9)-Cholestenol [Mass/volume] in Serum or Plasma,2.73
100425-8,DiHydro T-Mas [Mass/volume] in Serum or Plasma,2.73
100426-6,Squalene [Mass/volume] in Serum or Plasma,2.73
100427-4,Stigmasterol [Mass/volume] in Serum or Plasma,2.73
100428-2,Carnitine free and total and acylcarnitine panel - Urine,2.78
100429-0,LRBA deficiency panel - Blood,2.73
100430-8,Cells.LRBA+/Cells.CD3+CD14-CD45+ in Blood by Flow cytometry (FC),2.79
100431-6,Cells.CD3+CD14-CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC),2.73
100432-4,Cells.LRBA+/Cells.CD3-CD14-CD19+CD45+ in Blood by Flow cytometry (FC),2.79
100433-2,Cells.CD3-CD14-CD19+CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC),2.73
100434-0,Orthopoxvirus.non-variola DNA [Presence] in Specimen by NAA with probe detection,2.73
100435-7,Glial fibrillary acidic protein [Mass/volume] in Serum by Immunoassay,2.73
100436-5,Ubiquitin carboxyl-terminal hydrolase-L1 [Mass/volume] in Serum by Immunoassay,2.73
100437-3,Norsufentanil [Mass/volume] in Urine by Confirmatory method,2.73
10043-8,S wave amplitude in lead V4,2.48
100438-1,Adolescent medicine Outpatient Progress note,2.73
100439-9,Allergy and Immunology Outpatient Progress note,2.73
100440-7,Allergy Outpatient Progress note,2.73
100441-5,Attending Outpatient Progress note,2.73
100442-3,Audiology Outpatient Progress note,2.73
100443-1,Bariatric surgery Outpatient Progress note,2.73
100444-9,Blood banking and transfusion medicine Outpatient Progress note,2.73
100445-6,Bone Marrow Transplant Outpatient Progress note,2.73
10044-6,S wave amplitude in lead V5,2.48
100446-4,Breastfeeding Outpatient Progress note,2.73
100447-2,Burn management Outpatient Progress note,2.73
100448-0,Cardiac surgery Outpatient Progress note,2.73
100449-8,Cardiopulmonary Outpatient Progress note,2.78
100450-6,Child and adolescent psychiatry Outpatient Progress note,2.73
100451-4,Chiropractic medicine Outpatient Progress note,2.73
100452-2,Clinical cardiac electrophysiology Outpatient Progress note,2.73
10045-3,S wave amplitude in lead V6,2.48
100453-0,Clinical genetics Outpatient Progress note,2.73
100454-8,Clinical neurophysiology Outpatient Progress note,2.73
100455-5,Clinical pathology Outpatient Progress note,2.73
100456-3,Colon and rectal surgery Outpatient Progress note,2.73
100457-1,Consultant Outpatient Progress note,2.73
100458-9,Outpatient COVID-19 Intubation Progress note,2.73
100459-7,Outpatient COVID-19 Progress note,2.73
100460-5,Dermatology Outpatient Progress note,2.73
10046-1,S wave duration in lead AVF,2.48
100461-3,Developmental-behavioral pediatrics Outpatient Progress note,2.73
100462-1,Dialysis and Therapeutic apheresis Outpatient Progress note,2.73
100463-9,Eating disorders Outpatient Progress note,2.73
100464-7,Endocrinology Outpatient Progress note,2.73
100465-4,Family medicine Outpatient Progress note,2.73
100466-2,Gastroenterology Outpatient Progress note,2.73
100467-0,Geriatric medicine Outpatient Progress note,2.73
100468-8,Gynecologic oncology Outpatient Progress note,2.73
100469-6,Gynecology Outpatient Progress note,2.73
100470-4,Healthcare navigator Outpatient Progress note,2.73
100471-2,Heart failure Outpatient Progress note,2.73
100472-0,Heart failure+Transplant cardiology Outpatient Progress note,2.73
100473-8,Hematology Outpatient Progress note,2.73
100474-6,Hematology+Medical oncology Outpatient Progress note,2.73
100475-3,Hepatology Outpatient Progress note,2.73
100476-1,Immunology Outpatient Progress note,2.73
100477-9,Infectious disease Outpatient Progress note,2.73
100478-7,Internal medicine Outpatient Progress note,2.73
10047-9,S wave duration in lead AVL,2.48
100479-5,Interventional cardiology Outpatient Progress note,2.73
100480-3,Interventional radiology Outpatient Progress note,2.73
100481-1,Outpatient Mechanical circulatory support Progress note,2.73
100482-9,Medical Aid in Dying Outpatient Progress note,2.73
100483-7,Mental health Outpatient Progress note,2.73
100484-5,Multi-specialty program Outpatient Progress note,2.73
100485-2,Neonatal perinatal medicine Outpatient Progress note,2.73
100486-0,Nephrology Outpatient Progress note,2.73
10048-7,S wave duration in lead AVR,2.48
100487-8,Neurological surgery Outpatient Progress note,2.73
100488-6,Neurology Outpatient Progress note,2.73
100489-4,Neurology with special qualifications in child neurology Outpatient Progress note,2.73
100490-2,Nurse practitioner Outpatient Progress note,2.73
100491-0,Nurse Outpatient Progress note,2.73
100492-8,Nutrition and dietetics Outpatient Progress note,2.73
100493-6,Obstetrics and Gynecology Outpatient Progress note,2.73
100494-4,Obstetrics Outpatient Progress note,2.73
10049-5,S wave duration in lead I,2.48
100495-1,Occupational therapy Outpatient Progress note,2.73
100496-9,Oncology Outpatient Progress note,2.73
100497-7,Ophthalmology Outpatient Progress note,2.73
100498-5,Optometry Outpatient Progress note,2.73
100499-3,Oral and Maxillofacial Surgery Outpatient Progress note,2.73
100500-8,Orthopaedic surgery Outpatient Progress note,2.73
100501-6,Orthotics prosthetics Outpatient Progress note,2.73
100502-4,Otolaryngology Outpatient Progress note,2.73
10050-3,S wave duration in lead II,2.48
100503-2,Pain medicine Outpatient Progress note,2.73
100504-0,Palliative care Outpatient Progress note,2.73
100505-7,Pediatric cardiology Outpatient Progress note,2.73
100506-5,Pediatric dermatology Outpatient Progress note,2.73
100507-3,Pediatric endocrinology Outpatient Progress note,2.73
100508-1,Pediatric gastroenterology Outpatient Progress note,2.73
100509-9,Pediatric hematology-oncology Outpatient Progress note,2.73
100510-7,Pediatric infectious diseases Outpatient Progress note,2.73
10051-1,S wave duration in lead III,2.48
100511-5,Pediatric otolaryngology Outpatient Progress note,2.73
100512-3,Pediatric pulmonology Outpatient Progress note,2.73
100513-1,Pediatric rheumatology Outpatient Progress note,2.73
100514-9,Pediatric surgery Outpatient Progress note,2.73
100515-6,Pediatric transplant hepatology Outpatient Progress note,2.73
100516-4,Pediatric urology Outpatient Progress note,2.73
100517-2,Pharmacogenomics Outpatient Progress note,2.73
100518-0,Physical medicine and rehab Outpatient Progress note,2.73
100519-8,Physical therapy Outpatient Progress note,2.73
100520-6,Plastic surgery Outpatient Progress note,2.73
100521-4,Podiatry Outpatient Progress note,2.73
100522-2,Psychiatry Hospital Progress note,2.73
100523-0,Psychology Outpatient Progress note,2.73
100524-8,Pulmonary Outpatient Progress note,2.73
100525-5,Radiation oncology Outpatient Progress note,2.73
100526-3,Radiology Outpatient Progress note,2.73
100527-1,Recreational therapy Outpatient Progress note,2.73
100528-9,Reproductive endocrinology and infertility Outpatient Progress note,2.73
10052-9,S wave duration in lead V1,2.48
100529-7,Research Outpatient Progress note,2.73
100530-5,Rheumatology Outpatient Progress note,2.73
100531-3,Sleep medicine Outpatient Progress note,2.73
100532-1,Social worker Outpatient Progress note,2.73
100533-9,Solid Organ Transplant Outpatient Progress note,2.73
100534-7,Speech-language pathology Outpatient Progress note,2.73
100535-4,Spinal surgery Outpatient Progress note,2.73
100536-2,Sports medicine Outpatient Progress note,2.73
10053-7,S wave duration in lead V2,2.48
100537-0,Surgery of the hand Outpatient Progress note,2.73
100538-8,Telehealth+Outpatient Progress note,2.73
100539-6,Thromboembolism Outpatient Progress note,2.73
100540-4,Transplant surgery Outpatient Progress note,2.73
100541-2,Trauma Outpatient Progress note,2.73
100542-0,Urology Outpatient Progress note,2.73
100543-8,Vascular neurology Outpatient Progress note,2.73
100544-6,Vascular surgery Outpatient Progress note,2.73
10054-5,S wave duration in lead V3,2.48
100545-3,Wound care management Outpatient Progress note,2.73
100546-1,"Wound, Ostomy, and Continence Care Outpatient Progress note",2.73
100547-9,Adolescent medicine Hospital Progress note,2.73
100548-7,Allergy and Immunology Hospital Progress note,2.73
100549-5,Allergy Hospital Progress note,2.73
100550-3,Attending Hospital Progress note,2.73
100551-1,Audiology Hospital Progress note,2.73
10055-2,S wave duration in lead V4,2.48
100552-9,Bariatric surgery Hospital Progress note,2.73
100553-7,Blood banking and transfusion medicine Hospital Progress note,2.73
100554-5,Bone Marrow Transplant Hospital Progress note,2.73
100555-2,Breastfeeding Hospital Progress note,2.73
100556-0,Burn management Hospital Progress note,2.73
100557-8,Cardiac surgery Hospital Progress note,2.73
100558-6,Cardiopulmonary Hospital Progress note,2.78
100559-4,Child and adolescent psychiatry Hospital Progress note,2.73
10056-0,S wave duration in lead V5,2.48
100560-2,Clinical cardiac electrophysiology Hospital Progress note,2.73
100561-0,Clinical genetics Hospital Progress note,2.73
100562-8,Clinical neurophysiology Hospital Progress note,2.73
100563-6,Clinical pathology Hospital Progress note,2.73
100564-4,Colon and rectal surgery Hospital Progress note,2.73
100565-1,Consultant Hospital Progress note,2.73
100566-9,Dentistry Hospital Progress note,2.73
100567-7,Dermatology Hospital Progress note,2.73
100568-5,Developmental-behavioral pediatrics Hospital Progress note,2.73
100569-3,Dialysis and Therapeutic apheresis Hospital Progress note,2.73
100570-1,Eating disorders Hospital Progress note,2.73
100571-9,Endocrinology Hospital Progress note,2.73
100572-7,Family medicine Hospital Progress note,2.73
100573-5,Gastroenterology Hospital Progress note,2.73
100574-3,General medicine Hospital Progress note,2.73
100575-0,Geriatric medicine Hospital Progress note,2.73
100576-8,Gynecologic oncology Hospital Progress note,2.73
100577-6,Gynecology Hospital Progress note,2.73
10057-8,S wave duration in lead V6,2.48
100578-4,Healthcare navigator Hospital Progress note,2.73
100579-2,Heart failure Hospital Progress note,2.73
1005-8,Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma,2.73
100580-0,Heart failure+Transplant cardiology Hospital Progress note,2.73
100581-8,Hematology Hospital Progress note,2.73
100582-6,Hematology+Medical oncology Hospital Progress note,2.73
100583-4,Hepatology Hospital Progress note,2.73
100584-2,Immunology Hospital Progress note,2.73
100585-9,Infectious disease Hospital Progress note,2.73
10058-6,S' wave amplitude in lead AVF,2.48
100586-7,Internal medicine Hospital Progress note,2.73
100587-5,Interventional cardiology Hospital Progress note,2.73
100588-3,Interventional radiology Hospital Progress note,2.73
100589-1,Hospital Mechanical circulatory support Progress note,2.73
100590-9,Medical Aid in Dying Hospital Progress note,2.73
100591-7,Mental health Hospital Progress note,2.73
100592-5,Multi-specialty program Hospital Progress note,2.73
100593-3,Neonatal perinatal medicine Hospital Progress note,2.73
10059-4,S' wave amplitude in lead AVL,2.48
100594-1,Nephrology Hospital Progress note,2.73
100595-8,Neurological surgery Hospital Progress note,2.73
100596-6,Neurology Hospital Progress note,2.73
100597-4,Neurology with special qualifications in child neurology Hospital Progress note,2.73
100598-2,Nurse practitioner Hospital Progress note,2.73
100599-0,Nurse Hospital Progress note,2.73
100600-6,Nutrition and dietetics Hospital Progress note,2.73
100601-4,Obstetrics and Gynecology Hospital Progress note,2.73
10060-2,S' wave amplitude in lead AVR,2.48
100602-2,Obstetrics Hospital Progress note,2.73
100603-0,Occupational therapy Hospital Progress note,2.73
100604-8,Oncology Hospital Progress note,2.73
100605-5,Ophthalmology Hospital Progress note,2.73
100606-3,Oral and Maxillofacial Surgery Hospital Progress note,2.73
100607-1,Orthopaedic surgery Hospital Progress note,2.73
100608-9,Orthotics prosthetics Hospital Progress note,2.73
100609-7,Otolaryngology Hospital Progress note,2.73
10061-0,S' wave amplitude in lead I,2.48
100610-5,Pain medicine Hospital Progress note,2.73
100611-3,Palliative care Hospital Progress note,2.73
100612-1,Pastoral care Hospital Progress note,2.73
100613-9,Pediatric cardiology Hospital Progress note,2.73
100614-7,Pediatric dermatology Hospital Progress note,2.73
100615-4,Pediatric endocrinology Hospital Progress note,2.73
100616-2,Pediatric gastroenterology Hospital Progress note,2.73
100617-0,Pediatric hematology-oncology Hospital Progress note,2.73
100618-8,Pediatric infectious diseases Hospital Progress note,2.73
100619-6,Pediatric otolaryngology Hospital Progress note,2.73
100620-4,Pediatric pulmonology Hospital Progress note,2.73
100621-2,Pediatric rheumatology Hospital Progress note,2.73
100622-0,Pediatric surgery Hospital Progress note,2.73
100623-8,Pediatric transplant hepatology Hospital Progress note,2.73
100624-6,Pharmacogenomics Hospital Progress note,2.73
100625-3,Pharmacology Hospital Progress note,2.73
100626-1,Physical medicine and rehab Hospital Progress note,2.73
100627-9,Physical therapy Hospital Progress note,2.73
10062-8,S' wave amplitude in lead II,2.48
100628-7,Plastic surgery Hospital Progress note,2.73
100629-5,Podiatry Hospital Progress note,2.73
100630-3,Psychology Hospital Progress note,2.73
100631-1,Radiation oncology Hospital Progress note,2.73
100632-9,Radiology Hospital Progress note,2.73
100633-7,Rapid response team Hospital Progress note,2.81
100634-5,Recreational therapy Hospital Progress note,2.73
100635-2,Reproductive endocrinology and infertility Hospital Progress note,2.73
10063-6,S' wave amplitude in lead III,2.48
100636-0,Research Hospital Progress note,2.73
100637-8,Rheumatology Hospital Progress note,2.73
100638-6,Sleep medicine Hospital Progress note,2.73
100639-4,Social worker Hospital Progress note,2.73
100640-2,Solid Organ Transplant Hospital Progress note,2.73
100641-0,Speech-language pathology Hospital Progress note,2.73
100642-8,Spinal surgery Hospital Progress note,2.73
100643-6,Surgery of the hand Hospital Progress note,2.73
10064-4,S' wave amplitude in lead V1,2.48
100644-4,Thromboembolism Hospital Progress note,2.73
100645-1,Trauma Hospital Progress note,2.73
100646-9,Urology Hospital Progress note,2.73
100647-7,Vascular neurology Hospital Progress note,2.73
100648-5,Vascular surgery Hospital Progress note,2.73
100649-3,Wound care management Hospital Progress note,2.73
100650-1,"Wound, Ostomy, and Continence Care Hospital Progress note",2.73
10065-1,S' wave amplitude in lead V2,2.48
100651-9,Hospital COVID-19 Intubation Progress note,2.73
100652-7,Pure tone bone conduction threshold audiometry panel,2.73
100653-5,Pure tone air conduction threshold audiometry panel,2.73
100654-3,Pyruvate kinase M2 [Presence] in Stool,2.73
100655-0,XR Sella turcica Lateral,2.73
100656-8,Maternal and fetal medicine Outpatient Progress note,2.73
100657-6,Maternal and fetal medicine Telephone encounter+Hospital Progress note,2.73
100658-4,Hospital COVID-19 Progress note,2.73
100659-2,Maternal and fetal medicine Hospital Progress note,2.73
1006-6,Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells,2.73
100660-0,Maternal and fetal medicine Telephone encounter+Outpatient Progress note,2.73
100661-8,Psychiatry Outpatient Progress note,2.73
100662-6,Cortisol free and total panel - Serum or Plasma,2.73
100663-4,TPMT gene c.460G>A and c.719A>G [Presence] in Blood by Molecular genetics method,2.73
100664-2,NUDT15 gene c.50_55dup and c.415C>T [Presence] in Blood by Molecular genetics method,2.73
100665-9,NUDT15 gene c.415C>T [Presence] in Blood by Molecular genetics method,2.73
100666-7,NUDT15 gene c.416G>A [Presence] in Blood by Molecular genetics method,2.73
100667-5,NUDT15 gene c.52G>A [Presence] in Blood by Molecular genetics method,2.73
100668-3,NUDT15 gene c.50_55dup [Presence] in Blood by Molecular genetics method,2.73
10066-9,S' wave amplitude in lead V3,2.48
100669-1,NUDT15 gene c.50_55del [Presence] in Blood by Molecular genetics method,2.73
100670-9,RHD gene allele [Identifier] in Plasma cell-free DNA Nominal--fetus,2.73
100671-7,Aspergillus sp DNA [Presence] in Blood by NAA with probe detection,2.73
100672-5,Aspergillus fumigatus DNA [Presence] in Blood by NAA with probe detection,2.73
100673-3,Aspergillus terreus DNA [Presence] in Blood by NAA with probe detection,2.73
100674-1,BK virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100675-8,Cytomegalovirus DNA [Units/volume] (viral load) in Blood by NAA with probe detection,2.73
100676-6,Cytomegalovirus DNA [log units/volume] (viral load) in Blood by NAA with probe detection,2.73
10067-7,S' wave amplitude in lead V4,2.48
100677-4,Epstein Barr virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection,2.73
100678-2,Epstein Barr virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100679-0,Herpes virus 6 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection,2.73
100680-8,Herpes virus 6 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100681-6,Herpes virus 7 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection,2.73
100682-4,Herpes virus 7 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100683-2,Herpes virus 8 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection,2.73
100684-0,Herpes virus 8 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
10068-5,S' wave amplitude in lead V5,2.48
100685-7,JC virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection,2.73
100686-5,JC virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection,2.73
100687-3,JC virus DNA [Log #/volume] (viral load) in Urine by NAA with probe detection,2.73
100688-1,Parvovirus B19 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100689-9,Toxoplasma gondii DNA [Log #/volume] in Serum or Plasma by NAA with probe detection,2.73
100690-7,Toxoplasma gondii DNA [Log #/volume] in Cerebral spinal fluid by NAA with probe detection,2.73
100691-5,Varicella zoster virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection,2.73
100692-3,Varicella zoster virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection,2.73
10069-3,S' wave amplitude in lead V6,2.48
100693-1,Pneumocystis jirovecii DNA [Log #/volume] in Respiratory system specimen by NAA with probe detection,2.79
100694-9,SMN1 gene silent carrier analysis [Presence] in Blood or Tissue by Molecular genetics method,2.73
100695-6,Genetic disease analysis overall carrier interpretation in Blood or Tissue by Molecular genetics method Narrative,2.73
100696-4,CTNS related multigene analysis [Identifier] in Bodyfluid and Serum or Plasma by Molecular genetics method Nominal,2.73
100697-2,Interventional radiology Outpatient Note,2.73
100698-0,Social Determinants of Health screening report Document,2.73
100699-8,Rifabutin+Ethambutol [Susceptibility],2.73
100700-4,Trichomonas vaginalis DNA [Presence] in Urethra by NAA with probe detection,2.73
10070-1,S' wave duration in lead AVF,2.48
100701-2,Trichomonas vaginalis rRNA [Presence] in Urethra by NAA with probe detection,2.73
100702-0,Mycoplasma genitalium rRNA [Presence] in Urethra by NAA with probe detection,2.73
100703-8,Mycoplasma genitalium rRNA [Presence] in Urine by NAA with probe detection,2.73
100704-6,Mycoplasma genitalium rRNA [Presence] in Cervix by NAA with probe detection,2.73
100705-3,Mycoplasma genitalium rRNA [Presence] in Anorectal by NAA with probe detection,2.73
100706-1,Mycoplasma genitalium rRNA [Presence] in Specimen by NAA with probe detection,2.73
100707-9,Granulocytes [#/volume] in Peritoneal dialysis fluid by Automated count,2.79
100708-7,Plasma cells/Leukocytes in Synovial fluid,2.79
100709-5,Hepatocellular carcinoma risk [Score] by GAAD,2.73
100710-3,Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Throat by NAA with probe detection,2.73
100711-1,Borrelia burgdorferi.VlsE1+pepC10 Ab [Units/volume] in Serum by Immunoassay,2.74
100712-9,Brexpiprazole [Mass/volume] in Serum or Plasma,2.73
100713-7,Cariprazine [Mass/volume] in Serum or Plasma,2.73
100714-5,Guanfacine [Mass/volume] in Serum or Plasma,2.73
100715-2,Prothipendyl [Mass/volume] in Serum or Plasma,2.73
100716-0,Prostate specific Ag [Mass/volume] in DBS,2.73
100717-8,FCGR3A gene.p.Phe176Val [Presence] in Blood or Tissue by Molecular genetics method,2.73
100718-6,Undersea and hyperbaric medicine Discharge summary,2.73
10071-9,S' wave duration in lead AVL,2.48
100719-4,Surgical oncology Discharge summary,2.73
100720-2,Reproductive endocrinology and infertility Discharge summary,2.73
100721-0,Community health care Discharge summary,2.73
100722-8,Integrative medicine Discharge summary,2.73
100723-6,Sports medicine Discharge summary,2.73
100724-4,Diabetology Discharge summary,2.73
100725-1,Optometry Discharge summary,2.73
100726-9,Podiatry Discharge summary,2.73
10072-7,S' wave duration in lead AVR,2.48
100727-7,Chiropractic medicine Discharge summary,2.73
100728-5,Cardiac surgery Discharge summary,2.73
100729-3,Breastfeeding Discharge summary,2.73
100730-1,Transplant surgery Discharge summary,2.73
100731-9,Urgent care center Discharge summary,2.73
100732-7,Cholesterol.in lipoprotein (little a) and Cholesterol.in LDL panel - Serum,2.73
100733-5,Cholesterol in LDL [Mass/volume] in Serum by calculation --corrected for Cholesterol.in lipoprotein (little a),2.73
100734-3,traMADol and Metabolites Panel - Urine by Confirmatory method,2.73
10073-5,S' wave duration in lead I,2.48
100735-0,Mannose-6-phosphate isomerase and phosphomannomutase 1 panel - Leukocytes,2.73
100736-8,Acylcarnitine Analysis Post Mortem in Specimen Document,2.73
100737-6,Alkaline phosphatase.macromolecular [Presence] in Serum or Plasma,2.73
100738-4,Alanine aminotransferase.macromolecular [Presence] in Serum or Plasma,2.73
100739-2,Aspartate aminotransferase.macromolecular [Presence] in Serum or Plasma,2.73
1007-4,Direct antiglobulin test.polyspecific reagent [Presence] on Red Blood Cells,2.73
100740-0,Amylase.macromolecular [Presence] in Serum or Plasma,2.73
100741-8,Gamma glutamyl transferase.macromolecular [Presence] in Serum or Plasma,2.73
100742-6,Lactate dehydrogenase.macromolecular [Presence] in Serum or Plasma,2.73
10074-3,S' wave duration in lead II,2.48
100743-4,Lipase.macromolecular [Presence] in Serum or Plasma,2.73
100744-2,Alpha-1-acid glycoprotein [Mass/volume] in Serum or Plasma by Electrophoresis,2.73
100745-9,Chloride [Moles/volume] in Mixed venous blood,2.73
100746-7,Glucose [Moles/volume] in Mixed venous blood,2.73
100747-5,Legionella serogroup panel - Specimen,2.73
100748-3,Legionella spp [Presence] in Specimen by NAA with probe detection,2.73
100749-1,Legionella pneumophila serogroup 1 [Presence] in Specimen by NAA with probe detection,2.73
10075-0,S' wave duration in lead III,2.48
100750-9,Legionella pneumophila non-serogroup 1 [Presence] in Specimen by NAA with probe detection,2.73
100751-7,"Galactose-alpha-1,3-galactose (Alpha-Gal) panel - Serum or Plasma",2.73
100752-5,Exacerbating factors - Reported,2.73
100753-3,Alleviating factors - Reported,2.73
100754-1,Platelet disorders multigene analysis in Blood or Tissue by Sequencing,2.73
100755-8,Oligoclonal bands [#] in Serum or Plasma by Isoelectric focusing,2.73
100756-6,Oligoclonal bands [Interpretation] in Cerebral spinal fluid by Isoelectric focusing,2.73
100757-4,Protein fractions.oligoclonal bands panel - Serum and CSF by Isoelectric focusing,2.73
100758-2,Estimated lung age by based on clinical data,2.73
100759-0,Inspiratory reserve [Volume] Respiratory system by Spirometry,2.73
100760-8,XR Radius and Ulna - left Single view,2.73
100761-6,PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method,2.73
100762-4,HBA2 gene.c.377T>C [Presence] in Blood by Molecular genetics method,2.73
100763-2,Mycobacterium sp comparative reaction interpretation Narrative,2.73
100764-0,Mycobacterium bovis reaction wheal [Diameter] Qualitative --3 days post dose mammalian tuberculin intradermal,2.73
100765-7,Homocysteine and methylmalonate and methylcitrate panel - DBS,2.73
100766-5,Center for Epidemiologic Studies Depression Scale panel [CES-D],2.73
100767-3,Bothered by things that are not usually bothersome,2.73
10076-8,S' wave duration in lead V1,2.48
100768-1,Poor appetite,2.73
100769-9,Unhappy even with help from my family or friends,2.73
100770-7,Feeling just as good as others,2.73
100771-5,Trouble focusing,2.73
100772-3,Feeling depressed,2.73
100773-1,Feeling everything is too much of an effort,2.73
100774-9,Feeling hopeful about the future,2.73
100775-6,Feeling life had been a failure,2.73
10077-6,S' wave duration in lead V2,2.48
100776-4,Feeling fearful,2.73
100777-2,Restless sleep,2.73
100778-0,Feeling happy,2.73
100779-8,Quieter than usual,2.73
100780-6,Feeling lonely,2.73
100781-4,People were unfriendly,2.73
100782-2,Enjoying life,2.73
100783-0,Crying spells,2.73
10078-4,S' wave duration in lead V3,2.48
100784-8,Feeling sad,2.73
100785-5,Feeling people dislike me,2.73
100786-3,Lack of energy,2.73
100787-1,Total Score CES-D,2.73
100788-9,Stemphylium botryosum IgG4 Ab [Mass/volume] in Serum,2.73
100789-7,Rhizopus nigricans IgG4 Ab [Mass/volume] in Serum,2.73
100790-5,Lepidoglyphus destructor IgG Ab [Mass/volume] in Serum,2.73
100791-3,Hamster epithelium IgG Ab [Mass/volume] in Serum,2.73
10079-2,S' wave duration in lead V4,2.48
100792-1,Forsythia IgE Ab [Units/volume] in Serum,2.73
100793-9,Testosterone [Mass/volume] in Body fluid,2.73
100794-7,Follitropin [Units/volume] in Body fluid,2.74
100795-4,S100 calcium binding protein B [Mass/volume] in Body fluid,2.73
100796-2,Thyroglobulin [Mass/volume] in Body fluid,2.73
100797-0,Testosterone Free [Mass/volume] in Serum --1st specimen post XXX challenge,2.73
100798-8,Testosterone Free [Mass/volume] in Serum --2nd specimen post XXX challenge,2.73
100799-6,21-Deoxycortisol [Mass/volume] in Serum --1st specimen post XXX challenge,2.73
100-8,Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC),2.73
10080-0,S' wave duration in lead V5,2.48
100800-2,21-Deoxycortisol [Mass/volume] in Serum --2nd specimen post XXX challenge,2.73
100801-0,21-Deoxycortisol [Mass/volume] in Serum --3rd specimen post XXX challenge,2.73
100802-8,21-Deoxycortisol [Mass/volume] in Serum --4th specimen post XXX challenge,2.73
100803-6,21-Deoxycortisol [Mass/volume] in Serum --5th specimen post XXX challenge,2.73
100804-4,Vasopressin [Moles/volume] in Plasma --1st specimen post XXX challenge,2.73
100805-1,Vasopressin [Moles/volume] in Plasma --2nd specimen post XXX challenge,2.73
100806-9,Vasopressin [Moles/volume] in Plasma --3rd specimen post XXX challenge,2.73
100807-7,Vasopressin [Moles/volume] in Plasma --4th specimen post XXX challenge,2.73
100808-5,Vasopressin [Moles/volume] in Plasma --5th specimen post XXX challenge,2.73
100809-3,Vasopressin [Moles/volume] in Plasma --6th specimen post XXX challenge,2.73
100810-1,Vasopressin [Moles/volume] in Plasma --7th specimen post XXX challenge,2.73
100811-9,Vasopressin [Moles/volume] in Plasma --8th specimen post XXX challenge,2.73
100812-7,Vasopressin [Moles/volume] in Plasma --9th specimen post XXX challenge,2.73
100813-5,Vasopressin [Moles/volume] in Plasma --10th specimen post XXX challenge,2.73
100814-3,Vasopressin [Moles/volume] in Plasma --11th specimen post XXX challenge,2.73
100815-0,Vasopressin [Moles/volume] in Plasma --12th specimen post XXX challenge,2.73
100816-8,Glucagon [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge,2.73
100817-6,Glucagon [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge,2.73
10081-8,S' wave duration in lead V6,2.48
100818-4,Renin [Mass/volume] in Plasma --1st specimen post XXX challenge,2.73
100819-2,Renin [Mass/volume] in Plasma --2nd specimen post XXX challenge,2.73
1008-2,Indirect antiglobulin test.polyspecific reagent [Presence] in Serum or Plasma,2.73
100820-0,Renin [Mass/volume] in Plasma --3rd specimen post XXX challenge,2.73
100821-8,National POLST form: portable medical order panel,2.74
100822-6,Cardiopulmonary resuscitation orders,2.73
100823-4,Initial portable medical treatment orders,2.73
100824-2,Additional portable medical orders or instructions,2.73
100825-9,Medically assisted nutrition orders,2.73
10082-6,ST initial amplitude 6 ms in lead AVF,2.48
100826-7,Portable medical order AndOr advance directive review,2.73
100827-5,Portable medical order discussion participants,2.73
100828-3,Portable medical order administrative information,2.73
100829-1,Renin [Mass/volume] in Plasma --4th specimen post XXX challenge,2.73
100830-9,Alpha subunit free [Units/volume] in Serum or Plasma --1st specimen post XXX challenge,2.73
100831-7,Alpha subunit free [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge,2.73
100832-5,Alpha subunit free [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge,2.73
100833-3,Alpha subunit free [Units/volume] in Serum or Plasma --4th specimen post XXX challenge,2.73
10083-4,ST initial amplitude 6 ms in lead AVL,2.48
100834-1,Alpha subunit free [Units/volume] in Serum or Plasma --5th specimen post XXX challenge,2.73
100835-8,Alpha subunit free [Units/volume] in Serum or Plasma --6th specimen post XXX challenge,2.73
100836-6,Alpha subunit free [Units/volume] in Serum or Plasma --7th specimen post XXX challenge,2.73
100837-4,Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge,2.73
100838-2,Testosterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge,2.73
100839-0,Vitamin A/Retinol binding protein [Ratio] in Serum or Plasma,2.73
100840-8,IgE [Units/volume] in Body fluid,2.73
100841-6,Zinc finger protein of the cerebellum 4 Ab [Presence] in Cerebral spinal fluid by Line blot,2.73
10084-2,ST initial amplitude 6 ms in lead AVR,2.48
100842-4,Nonalcoholic steatohepatitis score in Serum or Plasma Calculated by FAST,2.73
100843-2,Liver fibrosis score in Serum or Plasma by Calculated.Agile3+,2.73
100844-0,Liver fibrosis score in Serum or Plasma by Calculated.Agile4,2.73
100845-7,Neurofascin155 IgG4 Ab [Presence] in Serum by Flow cytometry (FC),2.73
100846-5,Dengue virus 1+2+3+4 nsP1 IgG Ab [Presence] in Serum or Plasma by Immunoassay,2.73
100847-3,Gas and ammonia panel - Arterial blood,2.73
100848-1,Cell count and Differential panel - Amniotic fluid by Manual count,2.73
100849-9,Leukocytes [#/volume] in Amniotic fluid by Manual count,2.73
100850-7,Neutrophils [#/volume] in Amniotic fluid by Manual count,2.73
100851-5,Other cells [#/volume] in Amniotic fluid by Manual count,2.73
100852-3,NM Bones Views for metastasis W Sr-89 IV,2.73
100853-1,NM Pericardial space Views for effusion,2.81
100854-9,Lymphocytes/cells in Blood mononuclear cells by Immunoassay,2.79
100855-6,CD3 cells/cells in Blood mononuclear cells,2.79
100856-4,CD3+CD4+ (T4 helper) cells/cells in Blood mononuclear cells,2.79
100857-2,CD3+CD8+ (T8 suppressor) cells/cells in Blood mononuclear cells,2.79
100858-0,Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide,2.73
10085-9,ST initial amplitude 6 ms in lead I,2.48
100859-8,Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide,2.73
100860-6,Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide,2.73
100861-4,Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide,2.73
100862-2,Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide,2.73
100863-0,Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide,2.73
100864-8,Giardia lamblia bg gene [Genotype] in Specimen by Molecular genetics method,2.73
100865-5,Avian schistosomes DNA [Presence] in Specimen by NAA with probe detection,2.73
100866-3,Febrile antibody profile in Serum,2.73
10086-7,ST initial amplitude 6 ms in lead II,2.48
100867-1,Campylobacter jejuni+coli+lari+upsaliensis Ag [Presence] in Stool by Rapid immunoassay,2.73
100868-9,Cryptosporidium sp 18S-LC2 rRNA [Genotype] in Specimen by Molecular genetics method,2.73
100869-7,Cryptosporidium gp60 gene [Type] in Specimen by Molecular genetics method,2.73
100870-5,Cryptosporidium 18S rRNA [Genotype] in Specimen by Molecular genetics method,2.73
100871-3,Giardia lamblia gdh gene [Genotype] in Specimen by Molecular genetics method,2.73
100872-1,Bacteria producing polysaccharide from sucrose [Presence] in Isolate,2.73
100873-9,Giardia lamblia tpi gene [Genotype] in Specimen by Molecular genetics method,2.73
100874-7,Basidiobolus sp [Presence] in Specimen,2.73
10087-5,ST initial amplitude 6 ms in lead III,2.48
100875-4,Fetal Heart Document limited US,2.73
100876-2,Fetal Heart Document US,2.73
100877-0,US Heart Transesophageal during surgery,2.73
100878-8,Endoscopic ultrasound study Upper GI tract Document,2.73
100879-6,US Guidance for cryoablation of Breast - right,2.73
100880-4,US Guidance for cryoablation of Breast - left,2.73
100881-2,MR Guidance for cryoablation of Bone,2.73
100882-0,MR Peritoneum W contrast percutaneous intraperitoneal,2.73
10088-3,ST initial amplitude 6 ms in lead V1,2.48
100883-8,MR Guidance for biopsy of Kidney - left,2.73
100884-6,MR Guidance for biopsy of Kidney - right,2.73
100885-3,Parapoxvirus DNA [Presence] in Specimen by NAA with probe detection,2.73
100886-1,Orf virus DNA [Presence] in Specimen by NAA with probe detection,2.73
100887-9,Pseudocowpox virus DNA [Presence] in Specimen by NAA with probe detection,2.73
100888-7,Monkeypox virus clade II DNA [Presence] in Specimen by NAA with probe detection,2.74
100889-5,Monkeypox virus clade I DNA [Presence] in Specimen by NAA with probe detection,2.74
100890-3,Poxvirus DNA panel,2.73
10089-1,ST initial amplitude 6 ms in lead V2,2.48
100891-1,Orthopoxvirus IgG Ab [Presence] in Serum or Plasma by Immunoassay,2.73
100892-9,Orthopoxvirus IgM Ab [Presence] in Serum or Plasma by Immunoassay,2.73
100893-7,Orthopoxvirus IgG and IgM Ab panel - Serum or Plasma,2.73
100894-5,Recommended screening frequency Narrative,2.73
100895-2,Rickettsia conorii IgG and IgM [Interpretation] in Serum,2.73
100896-0,Vasopressin [Moles/volume] in Plasma --13th specimen post XXX challenge,2.73
100897-8,Staphylococcus aureus [Presence] in Specimen by Organism specific culture,2.73
100898-6,Lipid panel - Serum or Plasma,2.73
100899-4,Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype [Identifier] in Specimen by Organism specific culture,2.73
